CTOs on the Move


 
PanCare Health Offers Health Care Services In Multiple Locations, Including Freeport And Bonifay, FL For Urgent Care, Affordable Therapy, And More. Call Today!
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pancarefl.org
  • 403, East 11th Street
    Panama City, FL USA 32401
  • Phone: 850.747.5599

Executives

Name Title Contact Details

Similar Companies

American Board of Pain Medicine

American Board of Pain Medicine is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glenmark Generics Limited

Glenmark Generics Limited is a Mahwah, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.

Banner Pharmacaps Inc

Banner is a global gelatin-based drug delivery and specialty pharmaceutical company. We are committed to researching, developing and producing unique oral dosage forms for the Pharmaceutical Health Care Industry. Through our innovative technologies and

Avadim Health

Avadim Health is a life sciences company that offers advanced, safe solutions in everything from immune health to neuromuscular care. They are committed to helping those in need benefit from their products and have a strong pipeline across a broad rang...